Other Advocacy Initiatives

Canada’s Drug Agency (CDA) Recommends Reimbursement of Exagamglogene Autotemcel (CASGEVY) for the Treatment of Sickle Cell and Thalassemia Diseases.

On behalf of and with its Canadian member organizations, the GANSID advocated with the Canadian Agency for Drugs and Technologies in Health (CADTH) now known as Canada’s Drug Agency (CDA) regarding CASGEVY for the treatment of Sickle Cell Disease and Thalassemia. The GANSID recommends reimbursement of this curative therapy for all patients who are eligible for the therapy in Canada and we are pleased to announce that this advocacy work has received a positive reimbursement recommendation from CDA.

Submissions:

May 2024: Submission to support Canadian member organizations and people with Sickle Cell Disease
Link: https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0830-exa-cel-SCD_Patient_Clinician_Group_Input_Revised.pdf

May 2024: Submission to support Canadian member organizations and people with Thalassemia
Link: https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0831_Patient_Clinician_Group_Input.pdf

Reimbursement Recommendations:

The CDA is recommending reimbursement of this therapy with conditions. Read the CDA’s recommendations with the conditions on reimbursing the curative treatment at the link: https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0831_Casgevy_Draft_Recommendation.pdf
Member Organizations involved in this advocacy work are:
  1. Thalassemia Foundation of Canada
  2. Sickle Cell Awareness Group of Ontario
  3. Sickle Cell Disease Association of Atlantic Provinces
  4. Sickle Cell Awareness Network of Saskatchewan